Researcher:
Albayrak, Cem

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Cem

Last Name

Albayrak

Name

Name Variants

Albayrak, Cem

Email Address

Birth Date

Filters

2021 - 20222

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.753cffa8-d4e0-4ef6-bb60-ab9a24f66a3e

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Neovascularization of engineered tissues for clinical translation: where we are, where we should be?
    (American Institute of Physics (AIP) Publishing, 2021) Department of Chemical and Biological Engineering; N/A; Nazeer, Muhammad Anwaar; Karaoğlu, İsmail Can; Albayrak, Cem; Kızılel, Seda; Özer, Onur; PhD Student; PhD Student; Faculty Member; Department of Chemical and Biological Engineering; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); Graduate School of Sciences and Engineering; College of Engineering; N/A; N/A; N/A; 28376; N/A
    One of the key challenges in engineering three-dimensional tissue constructs is the development of a mature microvascular network capable of supplying sufficient oxygen and nutrients to the tissue. Recent angiogenic therapeutic strategies have focused on vascularization of the constructed tissue, and its integration in vitro; these strategies typically combine regenerative cells, growth factors (GFs) with custom-designed biomaterials. However, the field needs to progress in the clinical translation of tissue engineering strategies. The article first presents a detailed description of the steps in neovascularization and the roles of extracellular matrix elements such as GFs in angiogenesis. It then delves into decellularization, cell, and GF-based strategies employed thus far for therapeutic angiogenesis, with a particularly detailed examination of different methods by which GFs are delivered in biomaterial scaffolds. Finally, interdisciplinary approaches involving advancement in biomaterials science and current state of technological development in fabrication techniques are critically evaluated, and a list of remaining challenges is presented that need to be solved for successful translation to the clinics.
  • Thumbnail Image
    PublicationOpen Access
    Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro and in vivo
    (Wiley, 2022) Ulbegi Polat, Hivda; Yıldırım, İsmail Selim; Kayabölen, Alişan; Akcan, Uğur; Özturan, Doğancan; Şahin, Gizem Nur; Değirmenci, Nareg Pınarbaşı; Bayraktar, Canan; Söyler, Gizem; Sarayloo, Ehsan; Nurtop, Elif; Özer, Berna; Esken, Gülen Güney; Barlas, Tayfun; Doğan, Özlem; Karahüseyinoğlu, Serçin; Lack, Nathan Alan; Kaya, Mehmet; Albayrak, Cem; Can, Füsun; Solaroğlu, İhsan; Önder, Tuğba Bağcı; PhD Student; PhD Student; Master Student; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); Graduate School of Health Sciences; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 170418; 110772; 120842; 10486; N/A; 103165; 102059; 184359
    Soluble ACE2 (sACE2) decoys are promising agents to inhibit SARS-CoV-2, as their efficiency is unlikely to be affected by escape mutations. However, their success is limited by their relatively poor potency. To address this challenge, multimeric sACE2 consisting of SunTag or MoonTag systems is developed. These systems are extremely effective in neutralizing SARS-CoV-2 in pseudoviral systems and in clinical isolates, perform better than the dimeric or trimeric sACE2, and exhibit greater than 100-fold neutralization efficiency, compared to monomeric sACE2. SunTag or MoonTag fused to a more potent sACE2 (v1) achieves a sub-nanomolar IC50, comparable with clinical monoclonal antibodies. Pseudoviruses bearing mutations for variants of concern, including delta and omicron, are also neutralized efficiently with multimeric sACE2. Finally, therapeutic treatment of sACE2(v1)-MoonTag provides protection against SARS-CoV-2 infection in an in vivo mouse model. Therefore, highly potent multimeric sACE2 may offer a promising treatment approach against SARS-CoV-2 infections.